Healthy volunteers needed to set normal blood cell ranges for new analyzer
NCT ID NCT07031882
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This study aims to establish normal reference ranges for white blood cells and granulocytes using a new device called the Liberty Analyzer WBC System. About 300 healthy adults aged 21 and older will provide blood samples. The results will help doctors interpret future test results from this device.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Non-diseased adults.
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged ≥21 years old at the time of study entry * Able to provide written informed consent Exclusion Criteria: * Inadequate use and understanding of the English language, requiring a translator * Undergone tattooing or body piercing within the 7 days prior to the study visit * Undergone vaccination within the 7 days prior to the study visit * Episode of upper respiratory infection within the 30 days prior to the study visit * Use of oral corticosteroid medications within the 30 days prior to the study visit * Undergone surgery within the 90 days prior to the study visit * Been hospitalised within the 90 days prior to the study visit * Donated blood or plasma within the 90 days prior to the study visit * Pregnant at the time of the study visit * Breastfeeding at the time of the study visit * Current diagnosis of anemia (including iron deficiency anemia, vitamin deficiency anemia, aplastic anemia and/or hemolytic anemia) * Current diagnosis of high blood pressure * Current diagnosis of diabetes mellitus * History or current diagnosis of chronic kidney disease or end-stage renal disease * History or current diagnosis of cancer * History or current diagnosis of cardiovascular disease * History or current use of radiotherapy of the chest or abdomen * History or current diagnosis of the following conditions known to affect the CBC differential count: * Immune Thrombocytopenic Purpura (ITP) * Systemic Lupus Erythematosus (SLE) * Rheumatoid Arthritis (RA) * Antiphospholipid Syndrome (APS) * Sjogren's Syndrome * Tuberculosis (TB) * HIV * Hepatitis B/C * G6PD Deficiency * Sickle Cell Disease/Trait * Inflammatory Bowel Disease (IBD) * Eptein Barr virus * CMV Cytomegalovirus * Myelodysplastic Syndromes (MDS) / CMML * Asplenia Participants who meet the following criteria will be excluded a posteriori: * Hemoglobin, hematocrit, red cell and/or total white blood cell count obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site. * Iron, ferritin, transferrin, total Iron Binding Capacity (TIBC) and/or transferrin saturation results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site. * Alanine aminotransferase (ALT), aspartate aminotransferase ( AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, conjugated bilirubin, albumin and/or total protein results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site. * Creatinine, estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), sodium, potassium, chloride and/or bicarbonate results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site. * C-reactive protein (CRP) results obtained by standard laboratory analysis of the participant's venous blood sample, that fall outside of the applicable reference interval in use at the study site. * Self-report to be taking medication(s) that are subsequently identified as interfering substances for the Liberty Analyzer WBC System
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Exercise & Sport Nutrition Laboratory
College Station, Texas, 77843, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New sedative candidate goes Head-to-Head with propofol in early human test
- Can a Room-Temperature dairy drink build muscle?
- New injection MWN117 tested for safety in obesity
- Can a new drug avoid the high? soticlestat put to the test
- Liver trouble changes how drugs work: scientists test soticlestat
- Can a hard cycling sprint change a Heart-Calming peptide?